Posted by Michael Wonder on 18 Oct 2018
Health Canada has approved Invokana (canagliflozin) for reduction of major adverse cardiovascular events, the first SGLT2 inhibitor in Canada to receive this indication
17 October 2018 - Invokana has been shown to reduce the combined risk of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke in patients with type 2 diabetes and established cardiovascular disease by 18% compared to placebo.
Health Canada's approval is based on the findings from the CANVAS Program, which is the longest completed cardiovascular outcome program of any sodium glucose cotransporter-2 (SGLT2) inhibitor to-date.
The CANVAS Program evaluated the effect of Invokana on cardiovascular risk in a broad population of more than 10,000 adults with type 2 diabetes who had established cardiovascular disease or were at risk (with two or more risk factors) for cardiovascular disease.
